neratinib beats herceptin

[sarah]

Neratinib beats Herceptin in mid-stage trial • 11:31 AM

• Phase 2 clinical trial results show Puma Biotech's (PBYI +1.9%) cancer drug is more effective than Roche's (RHHBY -0.7%) in HER2 breast cancer patients when given before surgery.
• In the 193-patient trial, 39% of HER2 patients given the combination of neratinib and chemotherapy achieved a pathologic complete response compared to 23% who received Herceptin and chemo.
• Puma's drug is a pill whereas Roche's is given by infusion.
• ~25% of breast cancer cases are HER2 positive.

also see: http://www.ncbi.nlm.nih.gov/pubmed/24009064


would love to hear what dr slamon thinks